Tocotrienols are a less-studied form of vitamin E. Their most reliable effect is a modest lowering of inflammation and oxidative-damage markers, with weaker signals for liver fat and blood sugar. The old cholesterol claim has faded. Generally well tolerated, with mild stomach upset most common. A low-risk option where these markers are elevated; longevity benefits remain unproven. (Full Review)

Protocol

Dose

100–400 mg daily

Start at 100–200 mg and titrate up if tolerated

Source

Annatto delta/gamma

Tocopherol-free; avoid added alpha-tocopherol

Timing

With a fatty meal

Split dosing (twice daily) given short half-life

Time to effect

Inflammation markers

8–16 weeks

Lower inflammation and oxidative damage

Liver fat

8–16 weeks

Improved liver-fat and enzyme markers

Blood sugar

8–16 weeks

Modest glycemic improvement

Benefits

High: Reduced oxidative stress and inflammatory markers

Medium: Fatty liver markers, glycemic control in type 2 diabetes, cholesterol and triglyceride modulation

Low: Bone mineral density preservation, diabetic peripheral neuropathy, skin aging and photoprotection, immune function modulation

Speculative: Cancer chemoprevention, neuroprotection and stroke recovery, radioprotection, lifespan and cellular senescence

Contraindications

Active bleeding disorders

Therapeutic anticoagulation without monitoring

Surgery within ~2 weeks

Pregnancy and lactation

Key Interactions

Anticoagulants/antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin)

Statins (atorvastatin, simvastatin, rosuvastatin)

High-dose alpha-tocopherol (standard vitamin E supplements)

CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice)

Chemotherapy and targeted agents (bevacizumab, tamoxifen)

Blood-thinning supplements (fish oil, garlic, ginkgo, vitamin K)

Risk & Side Effects

Medium: Gastrointestinal discomfort

Low: Increased bleeding risk, paradoxical triglyceride elevation

Speculative: Pro-oxidant activity at high doses, unknown safety in pregnancy and lactation

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Primary inflammation marker; best-supported target
Fasting triglycerides	< 90 mg/dL	Detects benefit and the paradoxical high-dose increase
LDL cholesterol	< 100 mg/dL	Tracks the conflicted lipid effect
HbA1c	< 5.4%	Three-month average blood sugar
Fasting glucose	75–90 mg/dL	Complements HbA1c for glycemic response
ALT	< 25 U/L (men), < 20 U/L (women)	Liver enzyme; tracks fatty-liver benefit
INR	2.0–3.0 on warfarin	Detects added bleeding risk with blood thinners

Cadence: Baseline, recheck at 8–12 weeks, then every 6–12 months; INR within 1–2 weeks of starting if on anticoagulants

Qualitative Assessment

Energy and perceived vitality — steadier day-to-day energy
Digestive tolerance — absence of nausea or stomach discomfort
Skin condition — subjective hydration or resilience
Absence of bruising or bleeding — early flag, especially alongside blood thinners

Tocotrienols for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment